Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Halozyme (HALO) Stock Price & Analysis
781 Followers
HALO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$29.85 - $45.00
Previous Close$38.38
Volume433.90K
Average Volume (3M)1.15M
Market Cap
$4.92B
Enterprise Value$6.08B
Total Cash (Recent Filing)$336.00M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)18.2
Beta0.90
Next Earnings
May 07, 2024EPS Estimate
$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.11
Shares Outstanding126,824,800
10 Day Avg. Volume982,249
30 Day Avg. Volume1,151,205
Standard Deviation0.13
R-Squared0.27
Alpha0.00841
Financial Highlights & Ratios
Price to Book (P/B)-6.09
Price to Sales (P/S)21.16
Price to Cash Flow (P/CF)12.00
P/FCF Ratio11.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.34
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda13.43
Forecast
1Y Price Target
$51.00Price Target Upside34.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Long-term Financial ProjectionsHalozyme provides detailed five-year financial guidance, indicating significant growth in total revenues with expectations to achieve $1,565-1,690M by 2028.
Strategic PartnershipsExpectation of more partnerships that could drive upside to current projections for Halozyme, reinforcing confidence in the value potential of the Enhanze platform.
Technology Adoption And Market ShareThe Enhanze platform's ability to convert intravenous drugs to subcutaneous administration could capture a substantial market share in the $41.7B annual U.S. infusion therapy market.
Bears Say
Competitive PositionCompetitors have been announcing more new deals than HALO recently.
Financial ForecastsAnalyst lowers 12-month price target to $48 from the prior $61 per share, despite maintaining a Buy rating.
Revenue ConcernsThe analyst has reduced the Total Revenue projection for the first quarter to $191M, which is below the consensus estimate.
---
Ownership Overview
18.45% Insiders
34.85% Mutual Funds
29.27% Other Institutional Investors
17.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $29.85 and its highest was $45.00 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 19 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 20, 2024. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.799 by $0.021.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $0.69.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 127,054,240 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $0.82 in its last earnings report, beating expectations of $0.799. Following the earnings report the stock price went up 6.556%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 12M.
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (34.10% Upside)
$51.00 (34.10% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 205.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $130.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.65%
12-Months-Change
Fundamentals
Return on Equity
222.07%
Trailing 12-Months
Asset Growth
-5.88%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
HALO Company Deck
---
HALO Earnings Call
Q4 2024
0:00 / 0:00
---
HALO Stock 12 Months Forecast
Average Price Target
$51.00
▲(34.10% Upside)
Technical Analysis
Best Analysts Covering HALO
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+35.42%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +35.42% per trade.
---